Detalles de la búsqueda
1.
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Br J Cancer;
120(2): 190-195, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30585257
2.
Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer.
Pharmacogenomics J;
18(4): 556-564, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282362
3.
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Br J Clin Pharmacol;
84(6): 1389-1392, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29504153
4.
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Pharmacogenet Genomics;
23(3): 142-7, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23324806
5.
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
Eur J Cancer;
177: 154-163, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335783
6.
First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview.
J Clin Med;
10(3)2021 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33530547
7.
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.
Clin Colorectal Cancer;
17(2): e323-e329, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29551560
8.
SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.
Med Oncol;
34(8): 136, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28687963
Resultados
1 -
8
de 8
1
Próxima >
>>